抗登革病毒感染药物的研究进展  

Research progress on drugs against dengue virus infection

作　　者：高雅琪 张力健 姚秋凤 朱锐熙 卿立群 秦照玲 GAO Yaqi;ZHANG Lijian;YAO Qiufeng;ZHU Ruixi;QING Liqun;QIN Zhaoling(Dapartment of Medical Biodefense,Naval Medical University,Shanghai Key Laboratory of Medical Biodefense,Shanghai 200433,China)

机构地区：[1]海军军医大学生物医学防护教研室,上海市医学生物防护重点实验室,上海200433

出　　处：《生命的化学》2024年第10期1831-1839,共9页Chemistry of Life

摘　　要：登革热是一种由登革病毒(dengue virus,DENV)感染引起的蚊媒传染病,主要在热带、亚热带地区呈高发态势。全球每年约有320万感染病例,死亡2.2万例,是较为严重的全球性公共卫生问题。由于各种血清型病毒之间的交叉保护力弱以及存在抗体依赖性增强感染现象,登革热疫苗的预防效果有限,且尚无特效治疗药物。因此,研究开发新型抗DENV感染药物迫在眉睫。迄今为止,学术界已针对DENV感染开展了多种药物和候选化合物的抗病毒活性研究。本文对这些候选药物和化合物的种类进行分类,并对其研究进展和局限性展开综述。Dengue fever is a mosquito-borne infectious disease caused by dengue virus(DENV)infection,mainly in tropical and subtropical areas.Every year,there are about 3.2 million infections and 22000 deaths worldwide,so dengue virus infection is a serious global public health problem.Due to the heterologous infection of various serotypes and the increasing antibody dependence,the preventive effect of dengue vaccine is limited.There is no specific drug,so it is urgent to develop new anti-DENV infection drugs.Up to now,studies on antiviral activity of several drugs and candidate compounds have been carried out for DENV infection.In this paper,we classify the types of these candidate drugs and compounds,and their research progress and limitations are reviewed.

关 键 词：登革病毒 病毒感染 黄病毒 抗病毒药物 

分 类 号：R978.7[医药卫生—药品]